<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148264</url>
  </required_header>
  <id_info>
    <org_study_id>KKSH 079</org_study_id>
    <secondary_id>2010-018665-30</secondary_id>
    <nct_id>NCT01148264</nct_id>
  </id_info>
  <brief_title>Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis</brief_title>
  <acronym>COMFORT</acronym>
  <official_title>Efficacy of Olanzapine in Break-through Emesis After Prophylaxis With Dexamethasone, 5-HT3 Receptor Antagonists and Aprepitant Compared to Metoclopramide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karin Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to evaluate olanzapine compared to the metoclopramide in the treatment
      of break through emesis after prophylaxis with dexamethasone, 5-HT 3 receptor antagonists and
      aprepitant in patients receiving chemotherapy. Efficacy will be assessed using a modified
      MASCC questionaire with a visual analog scale.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrolment
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>three days</time_frame>
    <description>no vomitus, no further rescue medication, nausea &lt; 25mm on the visual analog scale (VAS) or reduction on the VAS of &gt;50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>five days</time_frame>
    <description>according to NCI-CTC-AE version4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 days</time_frame>
    <description>using EORTC-QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in urinary excretion of 5 hydroxy indole acetic acid</measure>
    <time_frame>5 days</time_frame>
    <description>measurement in 24 hours urine samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Emesis</condition>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>1x10mg per day for three days</description>
    <arm_group_label>olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <description>3x10mg per day for three days</description>
    <arm_group_label>metoclopramide</arm_group_label>
    <other_name>Paspertin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  break through emesis after prophylaxis with dexamethasone, 5-HT 3 receptor antagonists
             and aprepitant in patients receiving chemotherapy defined as vomitus or nausea&gt;25mm on
             VAS

          -  signed IC

        Exclusion Criteria:

          -  psychiatric disorders

          -  drug abuse

          -  pregnancy

          -  high dose chemotherapy

          -  treatment with other antiemetic drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin Jordan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martin-Luther-University Halle-Wittenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Martin-Luther-University Halle-Wittenberg, Department for Oncology and Hematology, Ernst-Grube-Strasse 40</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Karin Jordan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>break-through</keyword>
  <keyword>emesis</keyword>
  <keyword>break through emesis after prophylaxis with dexamethasone, 5-HT 3RA and aprepitant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

